10/19/2021 9:21:07 AM
Amgen Completes Acquisition Of Teneobio
10/7/2021 9:03:40 AM
Amgen Announces LUMAKRAS Combination Data From Phase 1b CodeBreaK 101 Study In Patients With KRAS G12C-mutated Cancers
10/7/2021 6:33:41 AM
Amgen, Neumora Therapeutics Collaborate To Advance Neuroscience Discovery, Development And Commercialization
10/2/2021 6:11:43 AM
Amgen And Kyowa Kirin Present Positive Data From Phase 2 Study Of AMG 451/KHK4083 At EADV Congress
9/20/2021 7:52:45 PM
Amgen Wins Patent Case On Otezla
9/20/2021 7:11:30 AM
Verastem Oncology,Amgen Partner To Evaluate VS-6766 In With LUMAKRASTM In Patients With KRAS G12C-Mutant NSCLC
9/16/2021 4:39:10 AM
Amgen Says LUMAKRAS With Vectibix Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated CRC
9/13/2021 9:01:57 AM
Amgen To Showcase Data From Inflammation Portfolio At EADV Virtual Congress 2021; Take Place Virtually Sept. 29 – Oct. 2
8/3/2021 4:03:27 PM
Amgen Q2 EPS $0.81 Vs. $3.05 Year Ago
7/30/2021 4:03:56 PM
Amgen Declares Quarterly Dividend Of $1.76/share, Payable Sept. 8/ Record Aug. 17